Phase 3 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a specific type of eye condition called choroidal neovascularization (abnormal blood vessel growth at the back of the eye) caused by age-related macular degeneration, which has not been treated before, in at least one eye (confirm with trial site for exact lesion types)
- People whose diagnosis of this wet form of age-related macular degeneration was made within the last 21 days before starting the study treatment
Who may not be able to join:
- People who have high blood pressure that is not well controlled at the time of screening
- People who have previously had laser treatment on the central part of the retina (macular laser photocoagulation) in the eye being studied
- People who have a history of uveitis (inflammation inside the eye) in either eye
- People who have had cataract surgery, a certain type of glaucoma surgery, or a specific laser eye procedure (YAG laser capsulotomy) in the study eye within the past 90 days
- People who have glaucoma (a pressure-related eye condition) in the study eye that is not well controlled
- People who have another active retinal disease in the study eye, beyond the condition this trial is investigating
- People who have previously received injections into the eye (such as anti-VEGF therapy or other intravitreal treatments) in the study eye
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Merck Sharp & Dohme LLC
Phone: 1-888-577-8839
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Mean Change in Best-Corrected Visual Acuity (BCVA) [Early Treatment of Diabetic Retinopathy Study (ETDRS Letters)] From Baseline to Year 1
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.